Inovio Pharmaceuticals Inc (INO) (Q3 2026) Earnings Call Highlights: FDA Approval, Commercial ...
HC Wainwright & Co. Reiterates Buy on Inovio Pharmaceuticals, Maintains $5 Price Target
Inovio Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
INOVIO to Participate in Upcoming Investor Conferences
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $6
Inovio (INO) Q3 2026 Earnings Call Transcript
Inovio Pharmaceuticals Q3 Earnings Call Highlights
Inovio: Q3 Earnings Snapshot
INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Inovio Pharmaceuticals, Inc. (INO) Q3 2026 Earnings Call Transcript
Inovio Pharmaceuticals Q3 EPS $(0.50) Misses $(0.21) Estimate, Sales $298.901K Miss $3.631M Estimate
Jefferies Maintains Buy on Inovio Pharmaceuticals, Raises Price Target to $8
Inovio stock tumbles 25% on $75M share offering
INOVIO Announces Pricing of Approximately $75 Million Public Offering
INOVIO Announces Proposed Public Offering of its Common Stock
INOVIO Pharmaceuticals Commences Common Stock Offering; No Terms Disclosed
Inovio: Upgrading To 'Buy' On Voceryq Accelerated Approval RRP And Competitive Advantages
INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026
INOVIO to Participate in Upcoming Scientific Conferences
Update: Inovio Shares Surge After HC Wainwright Upgrade Following FDA Approval for Voceryq
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.